ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK - Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
